TargaZyme, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.targazyme.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Phase 1
- Conditions
- Blood And Marrow TransplantationMyelodysplastic Syndrome (MDS)Transplantation InfectionLeukemiaLymphomaNon-Hodgkin's Lymphoma (NHL)Hodgkin's Lymphoma
- Interventions
- Drug: Fludarabine, Melphalan, ATG (Reduced Intensity)Drug: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Targazyme, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01983761
- Locations
- 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
News
No news found